Research programme: bacteriophage-based antibacterial therapeutics - Ampliphi Biosciences/Westmead Institute for Medical Research

Drug Profile

Research programme: bacteriophage-based antibacterial therapeutics - Ampliphi Biosciences/Westmead Institute for Medical Research

Latest Information Update: 13 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AmpliPhi Biosciences Corporation; Westmead Institute for Medical Research
  • Class Bacteriophages
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Bacterial infections

Most Recent Events

  • 09 Feb 2016 Early research in Bacterial infections in Australia (unspecified route)
  • 09 Feb 2016 The Westmead Institute for Medical Research and Ampliphi Biosciences agree to co-develop bacteriophage-based antibacterial therapeutics in Australia for Bacterial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top